The past few decades have witnessed the global emergency of methicillin-resistant Staphylococcus aureus (MRSA), and multiple-drug resistant Acinetobacter baumannii (MDRAB) which has rendered the treatment of infection difficult, leading to a higher mortality in patients. Unfortunately, very few novel classes of antibacterial drugs have been introduced, in part, due to difficulties in identifying new therapeutic targets for drug discovery. This discovery void created an unmet need for innovative drug discovery programs at pharmaceutical companies and academic institutions alike. In response to this unmet need, our team aim to discover new antibiotic with novel chemical scaffold against MRSA and MDRAB. To encourage young students and scientists to involve in new antibiotic study, we are now providing a variety of trainings, including drug design, drug synthesis, drug screening, drug efficacy study and drug mechanism study. We expect these training courses will bring more students and scientists from foreign country and Taiwan to work together to combat the antibiotic resistance problem.